ArticleDiscover oncology2026
Global trends in early-onset liver cancer incidence and projections to 2050 based on the global burden of disease study 2021.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly-onset liver cancer (EOLC) affects individuals aged 15–49 and poses a major global health challenge. This study evaluates health inequalities in EOLC burden across regions and sexes to support effective, targeted interventions
methodsUsing Global Burden of Disease (GBD) 2021 data, we analyzed global EOLC incidence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021. Analyses included Joinpoint regression, decomposition, locally estimated scatterplot smoothing (LOESS), and frontier efficiency assessment. Trends to 2050 were projected via a gender-stratified Bayesian age-period-cohort (BAPC) model.
resultsAbsolute EOLC burden increased globally, though age-standardized rates (ASRs) declined overall. Notably, age-standardized incidence rates (ASIRs) rose among women in high socio-demographic index (SDI) regions and among men in low-middle SDI regions. Hepatitis B virus (HBV) remained the leading cause, but alcohol, hepatitis C virus (HCV), and nonalcoholic steatohepatitis (NASH), especially in young women, showed increasing contributions. Population growth and aging drove increases in the absolute burden. Frontier analysis identified Mongolia as the lowest-performing country, while Somalia, Burundi, and Ethiopia achieved relatively efficient control. The BAPC model projects continued declines in ASR by 2050, yet female ASR is expected to rise modestly.
conclusionIn light of persistent gender and regional inequities and the rising impact of metabolic risks such as NASH, urgent and coordinated action is needed. Stakeholders must implement targeted etiology-specific strategies, prioritize early screening for high-risk groups—especially young women—and invest in stronger health systems in regions with the greatest need. These steps are critical to effectively reduce the global burden of EOLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.